Dilution of share value through the exercise of stock acquisition rights
First written in FY2021. 5 of 10 entries say "Mitigated", first in FY2022. Latest entry: FY2026-H1.
The whole theme swung hardest in 2017: 37 of 68 companies on the "Worse" side.
- FY2026-H1MaterialisedAnnual report
「The increases in the total number of issued shares, share capital and capital surplus resulted from the exercise of stock acquisition rights.」
During the current interim consolidated accounting period, 38,000 shares were issued through the exercise of stock acquisition rights. The disclosed number of shares remaining underlying the fifth series of stock acquisition rights was 467,800, indicating that some potential shares had been issued through actual exercises. - FY2025WorsenedAnnual report
「As of the filing date of this document, the number of potential shares from stock acquisition rights was 665,300, equivalent to 9.0% of the total 7,380,568 issued shares.」
The number of potential shares increased from 178,000, or 2.4%, in the previous fiscal year to 665,300, or 9.0%, following the issuance of the fifth series of stock acquisition rights. - FY2024MitigatedAnnual report
「As of the filing date of this document, the number of potential shares from stock acquisition rights was 178,000, equivalent to 2.4% of the total 7,380,568 issued shares.」
The number of potential shares decreased from 220,000, or 3.0%, in the previous fiscal year to 178,000, or 2.4%. - FY2024-Q2MitigatedAnnual report
「Fourth Series of Stock Acquisition Rights Number of stock acquisition rights: 1,530 (153,000 common shares)」
The number of shares underlying the fourth series of stock acquisition rights decreased from 161,000 to 153,000. - FY2023Potential shares updated to 220,000Annual report
「As of the filing date of this document, the number of potential shares from stock acquisition rights was 220,000, equivalent to 3.0% of the total 7,350,568 issued shares.」
The number of potential shares from stock acquisition rights was disclosed as 220,000, or 3.0% of the total issued shares. - FY2023-Q3MitigatedAnnual report
「Fourth Series of Stock Acquisition Rights: Number of stock acquisition rights: 1,800 (180,000 common shares)」
The number of shares underlying the fourth series of stock acquisition rights was 180,000, down from 203,000 in the previous disclosure. - FY2023-Q2MitigatedAnnual report
「① [Details of the stock option plan] Not applicable. ② [Status of other stock acquisition rights, etc.] Not applicable.」
Although the exercise of stock acquisition rights increased the number of shares by 30,000, it was disclosed that no stock options or other stock acquisition rights were outstanding as of the filing date. - FY2022MitigatedAnnual report
「As of the filing date of this document, the number of potential shares from stock acquisition rights was 258,000, equivalent to 3.3% of the total 7,768,768 issued shares.」
While 927,000 shares were issued through the exercise of the first to third series of stock acquisition rights, the number of potential shares after the grant of the fourth series was 258,000, or 3.3%. - FY2022-Q3MaterialisedAnnual report
「The stock acquisition rights issued by the company, from the first to the third series, were exercised by 14 September 2022, following the end of the third quarter of the current consolidated fiscal year, as outlined below.」
A total of 771,000 shares had been issued by the filing date through the exercise of the first to third series of stock acquisition rights, with some potential shares resulting in actual share issuances. - FY2021First statedAnnual report
「As of the filing date of this document, the number of potential shares from stock acquisition rights was 1,020,000, equivalent to 14.9% of the total 6,829,000 issued shares.」
The potential dilution of existing shareholders' equity value and voting rights from the exercise of stock options has been quantified.